A double-blind, randomized, placebo-controlled study of efficacy and tolerance of meloxicam treatment in patients with osteoarthritis of the knee

Scandinavian Journal of Rheumatology

Volumn 27, Issue 1, 1998, Pages 32-37

  Lund, B ^a,c   Distel, M ^b   Bluhmki, E ^b  

^a Tranehaven Hospital   (Denmark)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Knee; Meloxicam; NSAIDs; Osteoarthritis; Placebo

Indexed keywords

MELOXICAM; PARACETAMOL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KNEE JOINT; MALE; MIDDLE AGED; OSTEOARTHRITIS; PAIN MEASUREMENT; SAFETY; SEVERITY OF ILLNESS INDEX; THIAZINES; THIAZOLES; TREATMENT OUTCOME;

EID: 0031881839     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.1080/030097498441146     Document Type: Article

References (23)

1. Mazzuca SA, Brandt KD, Katz BP, Li W, Stewart KD. Therapeutic strategies distinguish community based primary care physicians from rheumatologists in the management of osteoarthritis. J Rheumatol 1993;20:80-6.
2. Roth SH, Bennett RE. Nonsteroidal anti-inflammatory drug gastropathy. Arch Intern Med 1987;147:2093-100.
3. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987;82:1153-8.
4. Churchill L, Graham AG, Shih C-K, Pauletti D, Farina PR, Grob PM. Selective inhibition of human cyclo-oxygenase-2 by meloxicam. Inflammopharmacology 1996;4:125-35.
5. Engelhardt G, Bögel R, Schnitzler Chr, Utzmann R. Meloxicam: influence on arachidonic acid metabolism. Part I. In vitro findings. Biochem Pharmacol 1996;51:21-8.
6. Pairet M, Engelhardt G. Differential inhibition of COX-1 and COX-2 in vitro and pharmacological profile in vivo of NSAIDs. In:Vane J, Botting J, Botting R. eds. Improved Non-steroid Anti-inflammatory Drugs: COX-2 Enzyme Inhibitors. Kluwer Academic Publishers: London 1996:103-19.
7. Frölich JC, Stichtenoth DO. NSAID: can renal side-effects be avoided? In:Vane J, Botting J, Botting R. eds. Improved Non-steroid Anti-inflammatory Drugs: COX-2 Enzyme Inhibitors. Kluwer Academic Publishers: London 1996:203-28.
8. Engelhardt G, Homma D, Schlegel K, Schnitzler CHR, Utzmann R. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 1995;44:423-33.
9. Stei P, Kruss B, Wiegleb J, Trach V. Local tissue tolerability of meloxicam, a new NSAID: indications for parenteral. dermal and mucosal administration. Br J Rheumatol 1996:35 Suppl 1:44-50.
10. Türck D, Roth W, Busch U. A review of the clinical pharmacokinetics of meloxicam. Br J Rheumatol 1996;35 Suppl 1:13-6.
11. Goei Thé H, Lund B, Distel M, Bluhmki E. A double blind, randomised trial comparing meloxicam with diclofenac in osteoarthritis (OA). Rheumatol Eur 1995;24 Suppl 3:E51.
12. Lindén B, Distel M, Bluhmki E. A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Br J Rheumatol 1996;35 Suppl 1:35-8.
13. Hosie J, Distel M, Bluhmki E. A six month, double blind study comparing meloxicam 15 mg with piroxicam 20 mg in osteoarthritis (OA). Rheumatol Eur 1995;24 Suppl 3:E50.
14. Hosie J, Distel M, Bluhmki E. Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium. Br J Rheumatol 1996;35 Suppl 1:39-43.
15. Levi S, Shaw-Smith C. Non-steroidal anti-inflammatory drugs: How do they damage the gut? Br J Rheumatol 1994;33:605-12.
16. Hudson N, Hawthorne AB, Cole AT, Jones PDE, Hawkey CJ. Mechanisms of gastric and duodenal damage and protection. Hepatogastroenterology 1992;39 Suppl 1:31-6.
17. Schoen RT, Vender RJ. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med 1989;86:449-58.
18. 2 synthesis and degradation in peptic ulcer disease. Scand J Gastroenterol 1987;22:425-30.
19. Distel M, Mueller C, Bluhmki E, Fries J. Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol 1996;35 Suppl 1:68-77.
20. Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual nonsteroidal anti-inflammatory drugs. Lancet 1994;343:769-72.
21. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991;114:257-63.
22. Garcia Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-72.
23. Bateman DN, Kennedy JG. Non-steroidal anti-inflammatory drugs and elderly patients. The medicine may be worse than the disease. Br Med J 1995;310:817-8.